Oxygen Biotherapeutics Receives Favorable NASDAQ Listing Decision
MORRISVILLE, N.C. -- May 16, 2013
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), today announced that the NASDAQ
Listing Qualifications Panel (the “Panel”) has granted the Company’s request
for continued listing on The NASDAQ Capital Market pursuant to an extension
through June 3, 2013 to evidence compliance with the minimum $1.00 bid price
requirement and through July 31, 2013 to evidence compliance with the minimum
$2.5 million stockholders’ equity requirement for continued listing on The
NASDAQ Capital Market.
The determination follows the Company’s hearing before the Panel on May 2,
2013, at which the Panel considered the Company’s plan to regain and sustain
compliance with the minimum bid price and stockholders’ equity requirements.
The Company is working to timely evidence compliance with the terms of the
Panel’s decision; however, there can be no assurance that it will be able to
“The panel’s decision is great news for shareholders. We are quite pleased
with the panel’s decision and appreciate their confidence in our ability to
meet and maintain compliance with NASDAQ’s requirements,” said Michael B.
Jebsen, Interim CEO and CFO of Oxygen Biotherapeutics.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical products that efficiently
deliver oxygen to tissues in the body. The company has developed a proprietary
perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte^® that is
currently in clinical and preclinical studies for intravenous delivery for
indications such as traumatic brain injury, decompression sickness and stroke.
The company is also developing PFC-based creams and gels for topical delivery
to the skin for dermatologic conditions and potentially wound care. In
addition, the Company has commercialized its Dermacyte^® line of skin care
cosmetics for the anti-aging market. Dermacyte is now out-licensed to Valor
Cosmetics of Switzerland.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company’s judgment as of
the date of this release. The forward-looking statements are subject to a
number of risks and uncertainties including the company’s ability to maintain
compliance with NASDAQ rules, delays in new product introductions and customer
acceptance of these new products, and other risks and uncertainties as
described in our filings with the Securities and Exchange Commission,
including in the current Form 10-Q filed on March 18, 2013, and our annual
report on Form 10-K filed on July 24, 2012, as well as other filings with the
SEC. The company disclaims any intent or obligation to update these
forward-looking statements beyond the date of this release. This caution is
made under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Oxygen Biotherapeutics, Inc.
Ellen Corliss, 919-855-2112
SVP, Investor Relations & Corporate Communications
Press spacebar to pause and continue. Press esc to stop.